Gunao-Yizhi decoction combined with donepezil for vascular dementia
A systematic review and meta-analysis

Yibin Hu, MMa, Lijuan Zhang, MDb, Xiuju Guan, MMc, Hanru Hou, MMc, Shuyue Bi, MMc, Changning Liu, MMc, Mingxiang Li, MMc, Kangfeng Wang, MD4,a

Abstract

Background: Gunao-Yizhi decoction has the effects of supplementing intelligence, strengthening marrow, resolving phlegm, and reducing turbidity. It is clinically used for the treatment of vascular dementia (VaD). However, there is still a lack of systematic evaluation of its efficacy and safety. This review conducted a systematic review of the current evidence on the efficacy and safety of Gunao-Yizhi decoction combined with donepezil for VaD.

Methods: China National Knowledge Infrastructure (CNKI), Wanfang database (Wanfang), Chinese Science and Technology Periodical Database (VIP), China Biology Medicine disc (CBM), MEDLINE, EMBASE, and Cochrane Library were searched for randomized controlled trials on Gunao-Yizhi decoction combined with donepezil for VaD. RevMan 5.3 software was used for data analysis.

Results: Twelve studies were obtained, including 1036 patients. Compared with donepezil alone, meta-analysis showed that Gunao-Yizhi decoction combined with donepezil could improve clinical efficacy, mini-mental state examination (MMSE) score, Hasegawa dementia scale (HDS), increase the level of superoxide dismutase (SOD) in serum, and reduce the level of malonaldehyde dismutases (MDA) in serum. The GRADE system was adopted to evaluate the outcome index. Clinical efficiency and the MMSE score were evaluated as very-low-quality evidence. HDS score, serum SOD level, and serum MDA level were evaluated as low-quality evidence.

Conclusion: Gunao-Yizhi decoction combined with donepezil has a significant prevalence in the treatment of vascular dementia, with no increase in adverse events. Gunao-Yizhi decoction can be recommended for routine use in the treatment of VaD.

Abbreviations: HDS = Hasegawa dementia scale, MDA = malonaldehyde dismutase, RCT = randomized controlled trial, MMSE = mini-mental status examination, SOD = superoxide dismutase, VaD = vascular dementia.

Keywords: donepezil, Gunao-Yizhi decoction, meta-analysis, vascular dementia

1. Introduction

Vascular dementia (VaD) is a serious manifestation of vascular cognitive impairment (VCI), accounting for 12 to 20% of all causes of dementia, only inferior to Alzheimer disease (AD). It can be secondary to stroke and other cerebrovascular diseases. Research shows that the prevalence of VaD in the elderly in China increases year by year. VaD has a significant impact on patients’ mental state and self-care ability, which causes a severe economic burden to patients and their families and causes enormous medical pressure on the country. At present, there is no specific cure for VaD. The best-studied treatments are cholinesterase inhibitors and memantine, both licensed and well-established drugs for Alzheimer disease, albeit with modest effectiveness. Traditional Chinese medicine plays a vital role in preventing and treating VaD, and it has been widely used in clinics.

Gunao-Yizhi decoction is a decoction for treating vascular dementia by tonifying kidney and removing phlegm. Its specific prescription includes 12g Rehmannia glutinosa (Shudi), 12g
Fructus Corni (Shanyurou), 12g Lycium barbarum (Gouqi), 12g Radix Polygoni Multiflori Preparata (Zhishouwu), 12g Ligustrum Lucidum (Nvzhenzi), 9g Rhodiola rosea (Hongjingtian), 9g Epimedium brevicornum (Yinyanghuo), 12g Semen Ziziphi Spinosae (Suanzaoren), 9g Acorus tatarinowii Schott (Shichangpu), Semen Astragali Complanati (Shayuanzi), 12g Salvia miltiorrhiza (Danshen), 9g Polygala tenuifolia (Yuanzhi), 18g Codonopsis pilosula (Dangshen), 12g Pueraria lobata (Gegen), 9g Rhizoma Chuanxiong (Chuanxiong), 9g Lumbricus (Dilong), 12g semen persicae (Taoren), 12g Caulis Piperis Kadsurae (Haifengteng). The above herbs are mixed with water, cooked until 400 mL of residual volume, and divided into 2 equal parts in terms of usage and dosage. Patients are suggested to take the warm mixture twice a day, once in the morning and once in the evening. Although Gunao-Yizhi decoction is widely used in the treatment of VaD, there has yet to be an objective evaluation of its clinical efficacy and safety. As a result, this paper will use a Cochrane systematic review to assess the efficacy of Gunao-Yizhi decoction and its modified prescriptions in combination with donepezil in the treatment of vascular dementia in order to provide an evidence-based basis for preventing and treating vascular dementia with traditional Chinese medicine.

---

**Figure 1.** PRISMA flow chart.
2. Data and Methods

2.1. Study registration

The protocol for this systematic review was registered on INPLASY and the registration number is INPLASY202240094 (URL= https://inplasy.com/inplasy-2022-4-0094/).

2.2. Research data

All randomized control trials of Gunao-Yizhi decoction combined with donepezil for VaD were included. Trials in English and Chinese were included.

2.3. Research methods

2.3.1. Literature inclusion criteria

Randomized controlled trials (RCTs) on VaD were included, including English and Chinese literature. Patients who are diagnosed with vascular dementia according to the Clinical Diagnostic Criteria of Vascular Dementia,[6] Diagnostic Efficacy Criteria of TCM Diseases,[6] or other diagnostic criteria for VaD. There was no specific restriction on age, gender, nationality, and race. The experimental groups were treated with Gunao-Yizhi decoction combined with donepezil, while the control groups were treated with donepezil alone.

2.3.2. Literature retrieval criteria

We reviewed databases including China National Knowledge Infrastructure (CNKI), Chinese Science and Technology Periodical Database (VIP), Wanfang database (Wanfang), China Biology Medicine disc (CBM), PubMed, MEDLINE, and Cochrane library. The search date for the system was built to April 1, 2022. We used keyword combinations to retrieve literature, such as Gunao-Yizhi decoction OR Gunao-Yizhi OR vascular dementia OR vascular cognitive impairment OR post-stroke dementia OR post-stroke cognitive impairment OR dementia OR VD OR VaD.

2.3.3. Literature exclusion criteria

Duplicate literature. Non-Chinese and non-English literature. Reviews. Non-human tests such as animal or cell tests. Medical experience summaries, case studies, and so on. RCTs that used other traditional Chinese medicine treatment methods, such as acupuncture, moxibustion, and others, may interfere with test results in addition to oral drugs.

2.3.4. Data extraction and quality assessment

Two researchers extracted the data independently and assessed the quality of the included trials. The literature’s inclusion and exclusion criteria were strictly followed. If 2 researchers disagreed on the selection of a literature, the literature would be given to a third researcher who would analyze it and decide whether or not to keep it. To assess the quality of evidence in each comparison, we used the grading of recommendations assessment, development, and evaluation (GRADE) system. The risk of publication, heterogeneity, indirectness, imprecision, and publication bias were all evaluated, and the results were classified as high, moderate, low, or very low.

2.3.5. Risk of bias assessment

Two researchers independently used the Cochrane risk-of-bias tool to methodological quality of the included trials. If there was insufficient data, we would try to contact the authors. If the data was missing, we would exclude the study.

2.3.6. Statistical analysis

We used RevMan 5.3 software for meta-analysis and heterogeneity test of literature. I square test was used to detect the heterogeneity among included trials. The trials with significant heterogeneity ($P < .10$, $I^2 > 50\%$) were analyzed by random effects model; For the trials with small heterogeneity ($P > .10$, $I^2 < 50\%$), the fixed effects model was used for analysis. The number of studies in each comparison was small, so there was no subgroup analysis performed. We used the method of excluding each study one by one for the sensitivity analysis.

2.4. Outcomes

Total effective rate, mini-mental status examination (MMSE) score are the main outcomes.

Hasegawa dementia scale (HDS) score, the level of serum superoxide dismutase (SOD), and the level of serum malonaldehyde dismutase (MDA) are the secondary outcomes.

In each included study, we also recorded adverse events to see if Gunao-Yizhi decoction increased the risk of adverse events.

2.5. Ethical approval

This study does not require ethical approval because it is based on previously published research.

3. Results

3.1. Literature search results

According to the search strategy, 128 studies were identified from the databases. We imported the studies into EndnoteX9 software, and 43 duplicate studies were removed, 60 studies such as animal experiments, medical reviews, and case reports were removed after reading the abstract and title, and 12 studies were finally included after reading the full text according to the inclusion and exclusion criteria. The PRISMA flow chart is shown in Figure 1.

| Literature source | Sample size (experimental group/control group) | Intervention measures (experimental group/control group) | Intervention time | Clinical outcomes |
|-------------------|-----------------------------------------------|---------------------------------------------------------|------------------|------------------|
| Gao Lu et al. 2018| 120 (60/60)                                    | Gunao-Yizhi decoction + Donepezil/Donepezil              | 3 mo             | ⑨⑩⑪⑫ |
| Li Yang et al. 2021| 60 (30/30)                                     | Gunao-Yizhi decoction + Donepezil/Donepezil              | 3 mo             | ⑨⑩⑪⑫ |
| Li Yang et al. 2019| 90 (45/45)                                     | Gunao-Yizhi decoction + Donepezil/Donepezil              | 3 mo             | ⑨⑩⑪⑫ |
| Liu Peng et al. 2019| 80 (40/40)                                     | Gunao-Yizhi decoction + Donepezil/Donepezil              | 1 mo             | ⑨ |
| Liu Xun et al. 2017| 55 (28/27)                                     | Gunao-Yizhi decoction + Donepezil/Donepezil              | 3 mo             | ⑨⑩⑪⑫ |
| Su Ying et al. 2017 | 68 (34/34)                                     | Gunao-Yizhi decoction + Donepezil/Donepezil              | 3 mo             | ⑨⑩⑪⑫ |
| Gui Xiong et al. 2017| 100 (50/50)                                   | Gunao-Yizhi decoction + Donepezil/Donepezil              | 3 mo             | ⑨⑩⑪⑫ |
| Sun Wei et al. 2015| 80 (40/40)                                     | Gunao-Yizhi decoction + Donepezil/Donepezil              | 3 mo             | ⑨⑩⑪⑫ |
| Wang Zheng et al. 2019| 90 (45/45)                                    | Gunao-Yizhi decoction + Donepezil/Donepezil              | 3 mo             | ⑨⑩⑪⑫ |
| Xue Li et al. 2021 | 72 (36/36)                                     | Gunao-Yizhi decoction + Donepezil/Donepezil              | 3 mo             | ⑨⑩⑪⑫ |
| Yang Shihui et al. 2017| 115 (60/55)                                   | Gunao-Yizhi decoction + Donepezil/Donepezil              | 1 mo             | ⑨ |
| Yuan Lan et al. 2017 | 100 (50/50)                                    | Gunao-Yizhi decoction + Donepezil/Donepezil              | 3 mo             | ⑨⑩⑪⑫ |

⑨Clinical efficiency; ⑩MMSE score; ⑪HDS score; ⑫Serum SOD Level; ⑬Serum MDA level.

HDS = Hasegawa dementia scale, MDA = malonaldehyde dismutase, MMSE = mini-mental status examination, SOD = superoxide dismutase.
3.2. Summary of the included studies

Finally, 12 studies with a total of 1036 patients were included. All of the studies included were in Chinese. All patients in the experimental group received Gunao-Yizhi decoction in combination with donepezil, while patients in the control group received donepezil alone. Summary of the included studies is shown in Table 1.

3.3. Assessment of risk of bias

Among the 12 studies included, only 3 trials adopted a random-number table, so these were classified as low risk.[8,9,16] 7 trials only mentioned random grouping without specifying the specific method, and these were considered as unclear risk.[7] 1 trial only explained grouping according to the treatment method, which was considered as high risk.[17] Because none of the studies mentioned allocation concealment or blinding, these were all regarded as unknown risk. There was no selective reporting in any of the studies, and it was unclear whether there was any other bias. The risk of bias in the included studies is shown in Figure 2.

3.4. Meta-analysis results

3.4.1. Total effective rate

Total effective rate is the sum of “significant effective rate” and “effective rate”. Six trials reported total effective rate (the criteria for judging the curative effect includes TCM syndrome standard and MMSE scoring standard), with a total of 479 patients. The heterogeneity test showed that $\chi^2 = 17\%$. The combined analysis of the fixed effects model showed that the difference in effective rate was statistically significant (RR = 1.40, 95% CI [1.25, 1.56], $P < .00001$), indicating that clinical efficiency of Gunao-Yizhi decoction combined with donepezil was higher than that of donepezil alone. The results are shown in Figure 3.

3.4.2. MMSE score

Nine trials reported MMSE scores, with a total of 839 patients.[7,9] There is significant heterogeneity among the included studies ($P = .004$, $I^2 = 63\%$). Sensitivity analysis revealed that excluding any study did not significantly reduce heterogeneity, which could be attributed to the control group’s intervention measures and the patients’ age. Gunao-Yizhi decoction combined with donepezil was better than donepezil alone in improving the MMSE scores of patients with vascular dementia (MD = 3.12, 95% CI [2.45, 3.78], $P < .00001$). The results are shown in Figure 4.

3.4.3. HDS score

Nine studies reported HDS scores with a total of 822 patients.[7,9] The heterogeneity test showed that $I^2 = 21\%$, which was combined and analyzed by fixed effects model. The results of the meta-analysis showed that Gunao-Yizhi decoction combined with donepezil was better than donepezil alone in improving the HDS score of patients with vascular dementia (MD = 3.62, 95% CI [3.11, 4.13], $P < .00001$). The results are shown in Figure 5.

3.4.4. Serum SOD level

Six studies reported SOD level, with a total of 569 patients.[7,8,14,15,17,18] The heterogeneity test showed that $I^2 = 23\%$, indicating no heterogeneity between groups. So fixed effects model was adopted. Meta-analysis showed that the effect of Gunao-Yizhi decoction combined with donepezil on reducing MDA levels in patients with vascular dementia (MD = -1.13, 95% CI [-1.34, -0.93], $P < .00001$) was significantly better than that of donepezil alone. The results are shown in Figure 7.

3.4.5. Serum MDA level

Six studies reported serum MDA level, with a total of 569 patients.[7,8,14,15,17,18] The heterogeneity test showed $I^2 = 0\%$, indicating no heterogeneity between

3.5. Adverse events

One study described patients’ adverse events after taking medicine, including 2 cases of stomach discomfort and 1 case of mild drowsiness in the experimental group; There were 2 cases of mild drowsiness in the control group, which did not cause
Figure 3. Forest plot of total effective rate.

Figure 4. Forest plot of MMSE score. MMSE = mini-mental status examination.

Figure 5. Forest plot of serum HDS level. HDS = Hasegawa dementia scale.

Figure 6. Forest plot of serum SOD level. SOD = superoxide dismutase.
serious adverse consequences. Other studies did not describe the occurrence of adverse events.

### 3.6. Quality of evidence

We applied the GRADE system to assess the quality of evidence for each outcome. The results suggested that four main factors reduce the quality of evidence: All the studies did not mention the blinding method or the specific implementation of the blinding method, which posed risk of serious bias; Patients may be heterogeneous due to inconsistent characteristics such as age and course of disease among studies; Total effective rate included a small number of samples so that the results may be inaccurate; There is statistical heterogeneity among the MMSE score groups. The GRADE evidence assessment showed that all the obtained evidence quality ratings were low to very low. The evaluation results are shown in Table 2.

### 4. Discussion

The etiology of vascular dementia is complex. Vascular dementia belongs to the category of “Dementia” and “Madness” in traditional Chinese medicine. Its manifestations are “Forgetfulness” and “Madness”, which have been recorded in Inner Canon of the Yellow Emperor. Deficiency and damage of all the 5 internal organs can lead to vascular dementia. Still, kidney deficiency can lead to brain impotence and tissue reduction because the kidney governs the bone and produces marrow. Because the kidney regulates the metabolism of water and fluid, when the storage of water and fluid ceases, phlegm turbidity develops, leading to dementia. As a result, despite the fact that the disease is located in the brain, VaD is most closely associated with kidney deficiency and phlegm turbidity. To treat vascular dementia, modern doctors begin by tonifying the kidney, filling essence, resolving phlegm, and opening orifices. In the prescription of Gunao-Yizhi decoction, rehmanna glutinosa, lycium barbarum, polygoni multiflori preparata, ligustrum lucidum are monkshood drugs, which are beneficial to filling marrow and nourishing kidney; rhodiola rosea, semen ziziphi spinosae, and polygala tenuifolia nourish the heart and intelligence; acorus tatarinowii schott-rhizoma Chuanxiong regulates the pathways related to neurodegenerative diseases and inflammatory vascular diseases acts on the endocrine system and nervous system and plays a role in the treatment of VaD through the way of tonifying the kidney and with the help of key targets such as APP, TNF, and JUN. Modern pharmacological studies have confirmed that salidroside extracted from rhodiola ppcan significantly improve the cognitive impairment of 2-VO rats and increase the level of long-term potentiation in the hippocampus to treat VaD; The ethanolic extract of fructus corni has antioxidant activity and protective effect of antioxidant enzyme system; The ethanol extract of semen astragali complanati has strong reducibility and antioxidant activity; codonopsis pilosula extract has the function of improving learning and memory.

According to the findings of this study, Gunao-Yizhi decoction combined with donepezil was more effective than donepezil alone in terms of clinical efficacy. Gunao-Yizhi decoction combined with donepezil is more effective than donepezil alone in improving MMSE scores. The combination of Gunao-Yizhi decoction and donepezil can improve HDS scores more than donepezil alone. Gunao-Yizhi decoction combined with donepezil is more effective than donepezil alone in improving serum SOD levels; in lowering serum MDA levels, Gunao-Yizhi decoction combined with donepezil is superior to donepezil alone in terms of improving cognitive function, increasing intelligence, and enhancing the anti-aging ability of the nervous system in patients with VaD. At the same time, this study also has some limitations. The literature included in this study is all Chinese literature published in domestic journals; The sample size of the included studies is small, and the impact of accidental events on the outcome cannot be excluded; There is a certain risk of bias in the included literature, which is embodied in random method, distribution concealment, blinding method implementation, outcome index, and so on; only 1 study reported the adverse reactions after medication; the safety research was insufficiently comprehensive. All of the GRADE evidence ratings are low or very low, implying that a larger sample size, stricter implementation of the distribution concealment and blinding method, and evaluation and demonstration of randomized controlled trials with more detailed records of adverse reactions are required to better guide clinical application.

### 5. Conclusion

To sum up, this study shows that combined therapy using Gunao-Yizhi decoction and donepezil had better effects on VaD than donepezil alone in terms of total effective rate, MMSE score, HDS score, serum SOD level and serum MDA level. As a result, combining Gunao-Yizhi decoction with donepezil can provide a certain reference value for clinical practice. However, larger sample size multi-center randomized controlled trials are required to provide a more reliable basis for its clinical application.
Table 2
GRADE evidence.

| No of studies | Design    | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Gunao-Yizhi decoction combined with donepezil | Donepezil | Relative (95% CI) | Absolute | Quality | Importance |
|---------------|-----------|--------------|---------------|--------------|-------------|---------------------|---------------------------------------------|-----------|-----------------|-----------|---------|------------|
| Clinical effectiveness | 6         | Randomized trials | Serious* | Serious† | No serious indirectness | None | 209/240 (87.1%) | 149/239 (62.3%) | 249 more per 1000 (from 156 more to 349 more) | 238 more per 1000 (from 149 more to 333 more) | RR 1.4 (1.25–1.56) | - | ⊕ΟΟΟ | Very low | Critical |
| MMSE score (better indicated by lower values) | 9         | Randomized trials | Serious* | Serious† | No serious indirectness | None | 422 | 417 | - | MD 3.12 higher (2.45–3.78 higher) | ⊕ΟΟΟ | Very low | Critical |
| HDS score (better indicated by lower values) | 9         | Randomized trials | Serious* | Serious† | No serious indirectness | No serious imprecision | None | 414 | 408 | - | MD 3.62 higher (3.11–4.13 higher) | ⊕ΟΟΟ | Low | Important |
| Serum SOD level (better indicated by lower values) | 6         | Randomized trials | Serious* | Serious† | No serious indirectness | No serious imprecision | None | 287 | 282 | - | MD 11.73 higher (9.96–13.5 higher) | ⊕ΟΟΟ | Low | Important |
| Serum MDA level (better indicated by lower values) | 6         | Randomized trials | Serious* | Serious† | No serious indirectness | No serious imprecision | None | 287 | 282 | - | MD 1.13 lower (1.34–0.93 lower) | ⊕ΟΟΟ | Low | Important |

*All the studies did not mention the blind method or the specific implementation of the blind method, which has a risk of serious bias.
† Patients may be heterogeneous due to inconsistent characteristics such as age and course of disease among studies.
‡ This group included a small number of samples so that the results may be inaccurate.
§ There was statistical heterogeneity among the MMSE score group.
HDS = Hasegawa dementia scale; MDA = malonaldehyde dismutase; MMSE = mini-mental status examination; SOD = superoxide dismutase.
Author contributions

Conceptualization: Yibin Hu, Lijuan Zhang, Kangfeng Wang.
Data curation: Lijuan Zhang, Xiuju Guan, Changning Liu.
Formal analysis: Xiuju Guan, Hanru Hou, Shuyue Bi, Mingxiang Li.
Methodology: Lijuan Zhang, Shuyue Bi, Changning Liu, Mingxiang Li.
Software: Xiuju Guan, Hanru Hou, Shuyue Bi.
Writing – original draft: Yibin Hu.
Writing – review & editing: Kangfeng Wang.

References

[1] Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American heart association/American stroke association. Stroke. 2011;42:2672–713.
[2] Chan KY, Wang W, Wu JJ, et al. Epidemiology of Alzheimer’s disease and other forms of dementia in China, 1990–2010: a systematic review and analysis. Lancet. 2013;381:2016–23.
[3] Xu J, Wang J, Wimo A, Fratiglioni L, et al. The economic burden of dementia in China, 1990–2030: implications for health policy. Bull World Health Organ. 2017;95:18–26.
[4] O'Brien JT, Thomas A. Vascular dementia. Lancet. 2015;386:1698–706.
[5] Jia JP, Wang SY. Discussion on clinical diagnostic criteria of vascular dementia. Chinese J Neuroimmunol Neurol. 2010; 17: 387–389
[6] National Administration of Traditional Chinese Medicine. Diagnostic efficacy criteria of clinical symptoms of traditional Chinese medicine. Beijing. 2017;33.
[7] Gao L. Clinical observation of Gunao-Yizhi decoction Combined with donepezil hydrochloride in the treatment of senile vascular dementia with kidney deficiency and phlegm turbidity. China’s Naturopathy. 2018;26:65–6.
[8] Li YY. Effects of Gunao-Yizhi decoction on oxidative stress response and hemorheological indexes in elderly patients with vascular dementia. Hubei J Trad Chinese Med. 2021;43:6–8.
[9] Yang SJ. Clinical efficacy of Gunao-Yizhi decoction combined with donepezil in the treatment of senile vascular dementia with kidney deficiency and phlegm turbidity. J Int Trad Chinese Med Western Med. 2017;26:590–59268.
[10] Huang XF. Efficacy of donepezil combined with Gunao-Yizhi decoction in the treatment of senile vascular dementia with kidney deficiency and phlegm turbidity. Heilongjiang Med. 2019;32:82–4.
[11] Xue LH. Effects of Gunao-Yizhi decoction on cognitive function and activities of daily living in elderly patients with vascular dementia. China Health Care. 2021;39:38–9.
[12] Yuan J. Observation on the therapeutic effect of Gunao-Yizhi decoction on senile vascular dementia. J Int Trad Chinese Med Western Med. 2017;26:590–59268.
[13] Guyatt GH, Oxman AD, Schünemann HJ, et al. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol. 2011;64:380–2.
[14] Yan ST, Li RL, Bai Y, et al. Research progress of addition and subtraction of rehmannia decoction in the treatment of vascular dementia. Mod Trad Chin Med. 2020;40:97–101.
[15] Liang MZ, Zhang BB, Liu GH, et al. Based on data mining and network pharmacology, explore the mechanism of Bushen-Huoxue Method in the treatment of vascular dementia J Liaon Univ Trad Chinese Med: 1–16 [2022–0403].
[16] Lv WH, Zheng T. Therapeutic effect of salidroside on cognitive impairment in rats with vascular dementia. J Neuroonat. 2021;37:443–8.
[17] Hwang KA, Hwang YJ, Song J. Antioxidant activities and oxidative stress inhibitory effects of ethanol extracts from Fructus Corni on raw 264.7 cells. BMC Complement Altern Med. 2016;16:1–9.
[18] Li YX. Clinical efficacy of Gunao-Yizhi decoction combined with donepezil in the treatment of senile vascular dementia with kidney deficiency and phlegm turbidity. Eur J Clin Med. 2017;4:937–40.
[19] Su YX. Clinical efficacy of Gunao-Yizhi decoction Combined with donepezil in the treatment of senile vascular dementia with kidney deficiency and phlegm turbidity. Chinese Med Guide. 2017;15:173–4.
[20] Sui XF, Ma H. Analysis of the clinical efficacy of Gunao-Yizhi decoction Combined with donepezil in the treatment of senile vascular dementia with kidney deficiency and phlegm turbidity. Clin Res Trad Chinese Med. 2017;9:17–9.
[21] Sun W, Zhang Q, Yang JB, Xu JF, et al. Clinical efficacy of Gunao-Yizhi decoction Combined with donepezil in the treatment of senile vascular dementia with kidney deficiency and phlegm turbidity. Chin J Gerontol. 2015;35:84–6.
[22] Wang Z, Huang XF. Efficacy of donepezil combined with Gunao-Yizhi decoction in the treatment of senile vascular dementia with kidney deficiency and phlegm turbidity. Heilongiang Med. 2019;32:82–4.
[23] Xue LH. Effects of Gunao-Yizhi decoction on cognitive function and activities of daily living in elderly patients with vascular dementia. China Health Care. 2021;39:38–9.
[24] Yang SJ. Clinical efficacy of Gunao-Yizhi decoction combined with donepezil in the treatment of senile vascular dementia with kidney deficiency and phlegm turbidity. Heilongjiang Med. 2019;32:82–4.
[25] Xue LH. Effects of Gunao-Yizhi decoction on cognitive function and activities of daily living in elderly patients with vascular dementia. China Health Care. 2021;39:38–9.
[26] Yuan J. Observation on the therapeutic effect of Gunao-Yizhi decoction on senile vascular dementia. J Int Trad Chinese Med Western Med. 2017;26:590–59268.
[27] Guyatt GH, Oxman AD, Schünemann HJ, et al. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol. 2011;64:380–2.
[28] Yan ST, Li RL, Bai Y, et al. Research progress of addition and subtraction of rehmannia decoction in the treatment of vascular dementia. Mod Trad Chin Med. 2020;40:97–101.
[29] Liang MZ, Zhang BB, Liu GH, et al. Based on data mining and network pharmacology, explore the mechanism of Bushen-Huoxue Method in the treatment of vascular dementia J Liaon Univ Trad Chinese Med: 1–16 [2022–0403].
[30] Lv WH, Zheng T. Therapeutic effect of salidroside on cognitive impairment in rats with vascular dementia. J Neuroonat. 2021;37:443–8.
[31] Hwang KA, Hwang YJ, Song J. Antioxidant activities and oxidative stress inhibitory effects of ethanol extracts from Fructus Corni on raw 264.7 cells. BMC Complement Altern Med. 2016;16:1–9.
[32] Wang L. Study on antioxidant activity of ethanol extract of Semen Astragali Complanati in vitro. Shaanxi Normal Univ. 2010.
[33] Wang H, Lin HQ, Tan J, et al. Research Progress on pharmacological action and clinical application of Codonopsis pilosula. World Latest Med Inf. 2019;19:21–2224.